Alnylam Pharmace. sell Biotechhunter
Summary
This prediction ended on 24.08.20 with a price of €111.76. With a performance of -2.83%, the SELL prediction by Biotechhunter was trending in the right direction. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -9.609% | -9.609% | 27.998% | 43.653% |
| iShares Core DAX® | 0.191% | 4.892% | 22.046% | 64.626% |
| iShares Nasdaq 100 | -0.614% | 2.901% | 7.804% | 109.421% |
| iShares Nikkei 225® | 0.599% | 7.404% | 22.218% | 57.591% |
| iShares S&P 500 | -0.036% | 3.489% | 4.833% | 68.003% |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.


